•
New Targeted Therapies:
•
Cabozantinib
(phase III randomized METEOR trial)
•
Approved in USA in April 2016 and in Europe in September 2016
•
Lenvatinib + everolimus
(phase II randomized study)
•
Approved in USA in May 2016 and in Europe in September 2016
•
Immunotherapy
•
Nivolumab
(phase III CheckMate 025)
•
Approved in USA in November 2016 and in Europe in April 2016
Progressive mRCC: Three New Options in 2017
